Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo(nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer

On June 6, 2022

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Chief Technology Officer Edmond Mesrobian Joins the WWD Tech Forum

Verisign to Report Second Quarter 2022 Financial Results

ENERGIZER HOLDINGS INC. TO WEBCAST A DISCUSSION OF THIRD QUARTER FISCAL 2022 RESULTS ON AUGUST 8